Lineage, Inc. Common Stock (LINE)vsRenX Enterprises Corp. (RENX)
LINE
Lineage, Inc. Common Stock
$35.99
-1.64%
REAL ESTATE · Cap: $8.93B
RENX
RenX Enterprises Corp.
$2.85
+6.74%
REAL ESTATE · Cap: $6.57M
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 65043% more annual revenue ($5.36B vs $8.22M). LINE leads profitability with a -1.9% profit margin vs -194.1%. RENX earns a higher WallStSmart Score of 38/100 (F).
LINE
Hold36
out of 100
Grade: F
RENX
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+75.9%
Fair Value
$161.49
Current Price
$35.99
$125.50 discount
Intrinsic value data unavailable for RENX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Revenue surging 4229.0% year-over-year
Areas to Watch
0.0% earnings growth
ROE of -1.2% — below average capital efficiency
Revenue declined 0.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -608.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : RENX
The strongest argument for RENX centers on Price/Book, Revenue Growth. Revenue growth of 4229.0% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.
Bear Case : RENX
The primary concerns for RENX are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 14.28 is elevated, increasing financial risk.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while RENX is a hypergrowth play — different risk/reward profiles.
RENX is growing revenue faster at 4229.0% — sustainability is the question.
LINE generates stronger free cash flow (78M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RENX scores higher overall (38/100 vs 36/100) and 4229.0% revenue growth. LINE offers better value entry with a 75.9% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Visit Website →RenX Enterprises Corp.
REAL ESTATE · REAL ESTATE - DEVELOPMENT · USA
RELX NV, through its interest in RELX Group plc, provides information and analysis for professional and commercial clients in all industries globally. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?